Ignite Limited IGN

Agilent Technologies has a company-confirmed earnings report dropping after the close on August 26, and every operating lever heading into that date is pointing the same direction. Here is what retirement-focused investors need to understand before the bell rings.

Ignite provides litigation risk, tax liability and contingent risk insurance solutions across the UK, Europe and the US.

The deal involves more than 500 skilled nursing facility beds from Atrium Health.

Aditxt’s Ignite unit has signed a merger agreement with SPAC Copley Acquisition Corp. and is expected to become a standalone NYSE-listed company.

Ignite will separate from Aditxt and is expected to become an independent public company called Ignite Proteomics.

Aditxt announced a definitive business combination agreement valuing its subsidiary, Ignite Proteomics, at $150 million.

No approved drug, clinical-stage asset, or competing research program targets the mechanisms that Liquid's Emerge platform identifies. FRAMINGHAM, MA / ACCESS Newswire / June 9, 2026 / Ignite Biomedical, Inc. ("Ignite") and Liquid Biosciences, developer ...

MOUNTAIN VIEW, Calif. & GOLDEN, Colo. & HONG KONG, June 09, 2026--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt"), a qualified acquisition corp and Ignite Proteomics, LLC ("Ignite", or "Ignite Proteomics"), a functional proteomics company and 100%-owned subsidiary of Aditxt, today announced that Ignite and strategic counterparty agreed to sign a definitive business combination agreement.

GOLDEN, Colo., June 08, 2026--Ignite Proteomics, LLC ("Ignite" or "Ignite Proteomics") a subsidiary of Aditxt, Inc. (NASDAQ: ADTX), today announced the launch of a prospective oncology registry enrolling up to 10,000 patients. The registry is designed to pair Ignite’s CLIA-certified Reverse Phase Protein Array ("RPPA") platform with structured clinical outcomes tracking to evaluate the real-world utility of functional proteomics in cancer therapy selection.

MOUNTAIN VIEW, Calif., June 01, 2026--Aditxt, Inc. (Nasdaq: ADTX)("Aditxt" or the "Company"), a life sciences platform company accelerating promising health innovations, today announced the appointment of Jeffrey M. Busch as Interim Chief Executive Officer of Aditxt, Inc., effective May 31, 2026. Mr. Busch, who has served as Chief Executive Officer of Aditxt's CLIA-certified precision oncology diagnostics subsidiary Ignite Proteomics, LLC ("Ignite") since March 2026, will now lead the full Aditx

The newly formed Verisk General Insurance UK & Ireland unit integrates the company’s international underwriting, IUPR, Claims UK and Ignite divisions.

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

Biomarker discovery opens the way for development of novel transformational technology in Autism Spectrum Disorder. FRAMINGHAM, MA / ACCESS Newswire / November 4, 2025 / Ignite Biomedical, Inc. ("Ignite"), a leader in AI-driven biomarker innovation ...